Dr. Martin Presents at BCVS 2026

Dr. Martin took the stage today at the American Heart Association's Basic Cardiovascular Sciences (BCVS) 2026 Scientific Sessions in Boston, presenting recent work from the lab on Hippo pathway inhibition as a strategy for treating ischemic heart failure.

His talk, "Inhibiting Hippo Signaling in Ischemic Heart Failure," was featured in Session 13: Cardiac Cellular Signaling — Mechanisms and Cross Talk, alongside presentations from investigators at Heidelberg University Hospital, the University of Washington, and UC San Diego. The session brought together some of the field's leading voices on the molecular pathways that govern how heart cells respond to injury and stress.

Photo: Dr. Martin presenting at BCVS 2026, American Heart Association.

Why It Matters

The Hippo signaling pathway acts as a natural brake on cell division. In the adult heart, that brake stays firmly engaged, which is part of why heart muscle can't regenerate after a heart attack. Our lab has spent years working to understand how releasing that brake, safely and selectively, could allow the heart to begin repairing itself. This talk brought that work to one of cardiovascular biology's most engaged audiences.

BCVS remains one of the premier meetings for basic and translational cardiovascular science, and it's always a highlight to see the lab's research presented alongside such a strong international lineup.